Friday, 20 Oct 2017

You are here

Ixekizumab Effective in TNF Failure Psoriatic Arthritis - SPIRIT-P2 Trial

Ixekizumab (Taltz) is currently approved for use in plaque psoriasis and is being developed for use in psoriatic arthritis (PsA). New results show IXE to be highly effective at skin and joint outcomes in PsA patients who have failed a TNF inhibitor (TNFi).

Previously, the SPIRT I trial demonstrated efficacy and safety of ixekizumab (IXE) in patients who were biologic DMARD-naive. In that 52-week study, 417 active PsA patients received either IXE 80 mg, IXE 40mg, adalumumab or placebo.  IXE patients showed significant improvement of arthritis, dactylitis and enthesitis along with impressive PASI 75 and PASI 90 results as well.

The current SPIRIT P2 trial assessed the efficacy of IXE in patient not responding to TNFi.  In this phase 3 trial, 363 adults with psoriatic arthritis were assigned (1:1:1) subcutaneous IXE 80 mg every 4 weeks or IXE every 2 weeks after a 160 mg starting dose or placebo. The primary endpoint was ACR-20 response at week 24.

At week 24, ACR-20 responses were higher with with IXE every 4 weeks (53%) and IXE every 2 weeks (48%) compared to placebo (20%).

Serious adverse events were low (3% IXE q4wk; 7% IXE q2wk; 3% placebo) and there were no deaths. Three (2%) serious infections, were seen in the IXE 2 weeks group.

Both the 2-week and 4-week ixekizumab dosing regimens improved the signs and symptoms of patients with active psoriatic arthritis and who had previously inadequate response to tumour necrosis factor inhibitors, with a safety profile consistent with previous studies investigating ixekizumab.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Tofacitinib Scores in TNF inhibitor Resistant Psoriatic Arthritis

Mease et al has reported in the NEJM the results of a phase 3 trial showing tofacitinib (Tofa) to be significantly more effective than placebo in active psoriatic arthritis (PsA) patients who previously failed to respond to tumor necrosis factor inhibitor (TNFi) therapies. 

Stelara FDA Approved for Use in Adolescent Psoriasis

Johnson & Johnson has announced that they have received an expanded FDA approval for the use of ustekinumab (Stelara) in treating adolescent patients, aged 12 and over, with moderate to severe plaque psoriais.

Spinal X-ray Inhibition in Ankylosing Spondylitis Best Achieved by Control of Activity

Although tumour necrosis factor inhibitors (TNFi) are highly effective (on clinical grounds) in ankylosing spondylitis (AS), proof that they may alter the course of spinal radiographic progression has been scant. That's primarily because of the insidisous nature of the disease, comparatively slow progression and difficulties in imaging and scoring the sacroiliac and axial joints. 

Alcohol Related Deaths Increased in Psoriasis

JAMA Dermatology has published a report showing psoriasis carries a 60% greater risk alcohol-related death compared with those without psoriasis. (Citation source: https://buff.ly/2galDwr)

Psoriasis Increases Risk of Major Adverse Cardiovascular Events

A report in the Journal of the American Academy of Dermatology shows that psoriasis duration and inflammation may result in cardiovascular inflammation and an increased risk of major adverse CV events.